Inmune Bio Advances CORDStrom Amid Funding Pressures

Inmune Bio ((INMB)) has held its Q1 earnings call. Read on for the main highlights of the call.

Inmune Bio’s latest earnings call painted a picture of steady operational progress offset by looming financial and execution risks. Management highlighted concrete steps toward regulatory filings and manufacturing readiness for CORDStrom, and ongoing work to further define XPro’s clinical profile. However, reduced R&D spending and a limited cash runway underscored the company’s dependence on timely approvals and future financing.

CORDStrom regulatory plan advances toward key filings

The company reported strong momentum on the regulatory front for CORDStrom, its lead program. It submitted a Pediatric Investigation Plan to the U.K. regulator, secured rapid assessment, and received feedback in April with no major issues, while drafting the five core sections of its Marketing Authorization Application for an early Q3 submission and aiming for parallel filings in Europe and the U.S.

Manufacturing validation and supply chain de-risking

Inmune Bio has begun the first of three process-validation manufacturing runs for CORDStrom, staying aligned with its MAA schedule. The firm also amended a material transfer agreement with the Anthony Nolan U.K. Cord Blood Bank, locking in long-term access to cord tissue and enabling U.S. lab testing required by regulators, which helps reduce supply and compliance risk ahead of commercialization.

Branding, definitions and launch groundwork for CORDStrom

The active ingredient in CORDStrom has now been officially named pobistrocel by the World Health Organization, with Ebstracel selected as the commercial name for the RDEB formulation. Management is preparing the necessary regulatory and commercial documentation and has enlisted TMC Pharma, a specialist in rare disease submissions, to orchestrate simultaneous EMA and FDA filings in support of an eventual launch.

XPro imaging work and partnering path

Beyond CORDStrom, the company is advancing imaging analyses from the MINDFuL study to further characterize XPro, focusing on MRI markers tied to myelin and structural brain integrity. These data are intended to support XPro’s positioning as a potential disease-modifying therapy, while management also evaluates rare disease indications and explores partnerships for later-stage development.

Net loss narrows on lower operating expenses

Financially, Inmune Bio posted a net loss attributable to common stockholders of $5.4 million for Q1 2026, down sharply from $9.7 million a year earlier. The roughly 44% improvement reflects reduced operating spending and provides temporary breathing room, though it may also signal tighter investment in its development pipeline.

R&D slowdown, steady G&A and limited runway

R&D expenses fell to $3.6 million in Q1 2026 from $7.6 million in Q1 2025, a drop of more than half, while general and administrative costs were essentially flat around $2.2 million. The company ended March with $21.4 million in cash and cash equivalents and about 26.6 million shares outstanding, and management believes this cash will fund operations only into Q1 2027.

Minor regulatory delays introduce schedule risk

Management acknowledged minor regulatory delays that pushed the planned MHRA submission for CORDStrom into early Q3. While described as modest, the slippage tightens the timetable for downstream EMA and FDA filings and raises some scheduling risk around the previously communicated end-of-year submission targets for the program.

Funding needs and impact of reduced R&D investment

The sizeable year-over-year reduction in R&D spending, while helping to curb losses, may indicate slower or more selective investment in development activities if it persists. Coupled with a cash runway that extends only through Q1 2027, investors should anticipate the possibility of new financing within roughly a year to sustain regulatory, manufacturing and commercialization plans.

Programs remain pre-commercial and execution dependent

Despite the progress described on the call, both CORDStrom and XPro remain pre-commercial assets, with approvals, validation runs and partnership deals still ahead. That leaves Inmune Bio exposed to the usual biotech risks around regulatory review, clinical data, manufacturing scale-up and deal-making, all of which must align for the current strategy to translate into revenue.

Forward outlook: filings in 2026 and manufacturing in 2027

Looking ahead, management reiterated that CORDStrom is on track for a U.K. MHRA submission in early Q3 2026, followed by parallel EMA and FDA filings targeting completion by the end of 2026. The company expects commercial manufacturing and supply to ramp in 2027, while operating under a leaner cost base and a cash position they say will support operations into Q1 2027.

Inmune Bio’s earnings call suggested a company nearing a crucial inflection point, with regulatory and manufacturing milestones for CORDStrom moving into focus and XPro’s profile slowly sharpening. Yet with programs still pre-commercial, a shortened runway and lower R&D spend, investors will be watching closely to see whether management can execute on filings, secure partners and raise capital without derailing momentum.